Life Biosciences Doses First Patient in Partial-Reprogramming Trial to Reverse Aging
MIT Technology Review·medium signal
Life Biosciences announced it dosed its first volunteer — a glaucoma patient — in an experimental partial-cellular-reprogramming therapy, as MIT Technology Review documents why 'reprogramming' has become the buzziest approach to reversing age-related disease. It's an early but concrete clinical milestone for a field that has largely lived in preclinical and venture hype.